Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D).
The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Granulocyte colony stimulating factor (GCSF)
- drug: Placebo (for GCSF)
- drug: Anti-Thymocyte Globulin (ATG)
- drug: Placebo (for ATG)
Eligibility
Inclusion Criteria:
- Must be > 12 years < 46
- Must have a diagnosis of T1D for less than 100 days at randomization
- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age
- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65
(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin
therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8
(ZnT8A)
- Must have stimulated C-peptide levels = 0.2 pmol/ml measured during a mixed meal
tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within
one month (37 days) of randomization
- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if EBV
seronegative at screening
- Be at least 6 weeks from last live immunization
- Participants are required to receive killed influenza vaccination at least 2 weeks
prior to randomization when vaccine for the current or upcoming flu season is
available
- Be willing to forgo vaccines during the treatment period and for 3 months following
last dose of study drug
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (<
3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800
lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).
- Have active signs or symptoms of acute infection at the time of randomization
- Have evidence of prior or current tuberculosis infection as assessed by purified
protein derivative (PPD), interferon gamma release assay (IGRA) or by history
- Be currently pregnant or lactating, or anticipate getting pregnant within the two year
study period
- Require use of other immunosuppressive agents including chronic use of systemic
steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or
Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may
interfere with study conduct, or cause increased risk to include pre-existing cardiac
disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,
neurological, or blood count abnormalities
- Have a history of malignancies other than skin
- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine
transaminase (ALT) greater than 3 times the upper limits of normal
- Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit
of normal
- Vaccination with a live virus within the last 6 weeks
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control
within prior 7 days of screening
- Active participation in another T1D treatment study in the previous 30 days
- Prior treatment with abatacept or anti-cd3
- Known allergy to GCSF or ATG
- Prior treatment with ATG or known allergy to rabbit derived products
- Any condition that in the investigator's opinion may adversely affect study
participation or may compromise the study results
Ages Eligible for Study
12 Years - 45 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D).
The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Granulocyte colony stimulating factor (GCSF)
- drug: Placebo (for GCSF)
- drug: Anti-Thymocyte Globulin (ATG)
- drug: Placebo (for ATG)
Eligibility
Inclusion Criteria:
- Must be > 12 years < 46
- Must have a diagnosis of T1D for less than 100 days at randomization
- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age
- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65
(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin
therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8
(ZnT8A)
- Must have stimulated C-peptide levels = 0.2 pmol/ml measured during a mixed meal
tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within
one month (37 days) of randomization
- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if EBV
seronegative at screening
- Be at least 6 weeks from last live immunization
- Participants are required to receive killed influenza vaccination at least 2 weeks
prior to randomization when vaccine for the current or upcoming flu season is
available
- Be willing to forgo vaccines during the treatment period and for 3 months following
last dose of study drug
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (<
3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800
lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).
- Have active signs or symptoms of acute infection at the time of randomization
- Have evidence of prior or current tuberculosis infection as assessed by purified
protein derivative (PPD), interferon gamma release assay (IGRA) or by history
- Be currently pregnant or lactating, or anticipate getting pregnant within the two year
study period
- Require use of other immunosuppressive agents including chronic use of systemic
steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or
Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may
interfere with study conduct, or cause increased risk to include pre-existing cardiac
disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,
neurological, or blood count abnormalities
- Have a history of malignancies other than skin
- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine
transaminase (ALT) greater than 3 times the upper limits of normal
- Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit
of normal
- Vaccination with a live virus within the last 6 weeks
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control
within prior 7 days of screening
- Active participation in another T1D treatment study in the previous 30 days
- Prior treatment with abatacept or anti-cd3
- Known allergy to GCSF or ATG
- Prior treatment with ATG or known allergy to rabbit derived products
- Any condition that in the investigator's opinion may adversely affect study
participation or may compromise the study results
Ages Eligible for Study
12 Years - 45 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D).
The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Granulocyte colony stimulating factor (GCSF)
- drug: Placebo (for GCSF)
- drug: Anti-Thymocyte Globulin (ATG)
- drug: Placebo (for ATG)
Eligibility
Inclusion Criteria:
- Must be > 12 years < 46
- Must have a diagnosis of T1D for less than 100 days at randomization
- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age
- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65
(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin
therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8
(ZnT8A)
- Must have stimulated C-peptide levels = 0.2 pmol/ml measured during a mixed meal
tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within
one month (37 days) of randomization
- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if EBV
seronegative at screening
- Be at least 6 weeks from last live immunization
- Participants are required to receive killed influenza vaccination at least 2 weeks
prior to randomization when vaccine for the current or upcoming flu season is
available
- Be willing to forgo vaccines during the treatment period and for 3 months following
last dose of study drug
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (<
3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800
lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).
- Have active signs or symptoms of acute infection at the time of randomization
- Have evidence of prior or current tuberculosis infection as assessed by purified
protein derivative (PPD), interferon gamma release assay (IGRA) or by history
- Be currently pregnant or lactating, or anticipate getting pregnant within the two year
study period
- Require use of other immunosuppressive agents including chronic use of systemic
steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or
Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may
interfere with study conduct, or cause increased risk to include pre-existing cardiac
disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,
neurological, or blood count abnormalities
- Have a history of malignancies other than skin
- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine
transaminase (ALT) greater than 3 times the upper limits of normal
- Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit
of normal
- Vaccination with a live virus within the last 6 weeks
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control
within prior 7 days of screening
- Active participation in another T1D treatment study in the previous 30 days
- Prior treatment with abatacept or anti-cd3
- Known allergy to GCSF or ATG
- Prior treatment with ATG or known allergy to rabbit derived products
- Any condition that in the investigator's opinion may adversely affect study
participation or may compromise the study results
Ages Eligible for Study
12 Years - 45 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D).
The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Granulocyte colony stimulating factor (GCSF)
- drug: Placebo (for GCSF)
- drug: Anti-Thymocyte Globulin (ATG)
- drug: Placebo (for ATG)
Eligibility
Inclusion Criteria:
- Must be > 12 years < 46
- Must have a diagnosis of T1D for less than 100 days at randomization
- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age
- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65
(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin
therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8
(ZnT8A)
- Must have stimulated C-peptide levels = 0.2 pmol/ml measured during a mixed meal
tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within
one month (37 days) of randomization
- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if EBV
seronegative at screening
- Be at least 6 weeks from last live immunization
- Participants are required to receive killed influenza vaccination at least 2 weeks
prior to randomization when vaccine for the current or upcoming flu season is
available
- Be willing to forgo vaccines during the treatment period and for 3 months following
last dose of study drug
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (<
3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800
lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).
- Have active signs or symptoms of acute infection at the time of randomization
- Have evidence of prior or current tuberculosis infection as assessed by purified
protein derivative (PPD), interferon gamma release assay (IGRA) or by history
- Be currently pregnant or lactating, or anticipate getting pregnant within the two year
study period
- Require use of other immunosuppressive agents including chronic use of systemic
steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or
Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may
interfere with study conduct, or cause increased risk to include pre-existing cardiac
disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,
neurological, or blood count abnormalities
- Have a history of malignancies other than skin
- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine
transaminase (ALT) greater than 3 times the upper limits of normal
- Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit
of normal
- Vaccination with a live virus within the last 6 weeks
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control
within prior 7 days of screening
- Active participation in another T1D treatment study in the previous 30 days
- Prior treatment with abatacept or anti-cd3
- Known allergy to GCSF or ATG
- Prior treatment with ATG or known allergy to rabbit derived products
- Any condition that in the investigator's opinion may adversely affect study
participation or may compromise the study results
Ages Eligible for Study
12 Years - 45 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D).
The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Granulocyte colony stimulating factor (GCSF)
- drug: Placebo (for GCSF)
- drug: Anti-Thymocyte Globulin (ATG)
- drug: Placebo (for ATG)
Eligibility
Inclusion Criteria:
- Must be > 12 years < 46
- Must have a diagnosis of T1D for less than 100 days at randomization
- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age
- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65
(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin
therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8
(ZnT8A)
- Must have stimulated C-peptide levels = 0.2 pmol/ml measured during a mixed meal
tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within
one month (37 days) of randomization
- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if EBV
seronegative at screening
- Be at least 6 weeks from last live immunization
- Participants are required to receive killed influenza vaccination at least 2 weeks
prior to randomization when vaccine for the current or upcoming flu season is
available
- Be willing to forgo vaccines during the treatment period and for 3 months following
last dose of study drug
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (<
3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800
lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).
- Have active signs or symptoms of acute infection at the time of randomization
- Have evidence of prior or current tuberculosis infection as assessed by purified
protein derivative (PPD), interferon gamma release assay (IGRA) or by history
- Be currently pregnant or lactating, or anticipate getting pregnant within the two year
study period
- Require use of other immunosuppressive agents including chronic use of systemic
steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or
Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may
interfere with study conduct, or cause increased risk to include pre-existing cardiac
disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,
neurological, or blood count abnormalities
- Have a history of malignancies other than skin
- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine
transaminase (ALT) greater than 3 times the upper limits of normal
- Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit
of normal
- Vaccination with a live virus within the last 6 weeks
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control
within prior 7 days of screening
- Active participation in another T1D treatment study in the previous 30 days
- Prior treatment with abatacept or anti-cd3
- Known allergy to GCSF or ATG
- Prior treatment with ATG or known allergy to rabbit derived products
- Any condition that in the investigator's opinion may adversely affect study
participation or may compromise the study results
Ages Eligible for Study
12 Years - 45 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D).
The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Granulocyte colony stimulating factor (GCSF)
- drug: Placebo (for GCSF)
- drug: Anti-Thymocyte Globulin (ATG)
- drug: Placebo (for ATG)
Eligibility
Inclusion Criteria:
- Must be > 12 years < 46
- Must have a diagnosis of T1D for less than 100 days at randomization
- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age
- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65
(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin
therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8
(ZnT8A)
- Must have stimulated C-peptide levels = 0.2 pmol/ml measured during a mixed meal
tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within
one month (37 days) of randomization
- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if EBV
seronegative at screening
- Be at least 6 weeks from last live immunization
- Participants are required to receive killed influenza vaccination at least 2 weeks
prior to randomization when vaccine for the current or upcoming flu season is
available
- Be willing to forgo vaccines during the treatment period and for 3 months following
last dose of study drug
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (<
3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800
lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).
- Have active signs or symptoms of acute infection at the time of randomization
- Have evidence of prior or current tuberculosis infection as assessed by purified
protein derivative (PPD), interferon gamma release assay (IGRA) or by history
- Be currently pregnant or lactating, or anticipate getting pregnant within the two year
study period
- Require use of other immunosuppressive agents including chronic use of systemic
steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or
Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may
interfere with study conduct, or cause increased risk to include pre-existing cardiac
disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,
neurological, or blood count abnormalities
- Have a history of malignancies other than skin
- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine
transaminase (ALT) greater than 3 times the upper limits of normal
- Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit
of normal
- Vaccination with a live virus within the last 6 weeks
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control
within prior 7 days of screening
- Active participation in another T1D treatment study in the previous 30 days
- Prior treatment with abatacept or anti-cd3
- Known allergy to GCSF or ATG
- Prior treatment with ATG or known allergy to rabbit derived products
- Any condition that in the investigator's opinion may adversely affect study
participation or may compromise the study results
Ages Eligible for Study
12 Years - 45 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting